These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1105 related articles for article (PubMed ID: 23809766)
1. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766 [TBL] [Abstract][Full Text] [Related]
2. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM; Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497 [TBL] [Abstract][Full Text] [Related]
8. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Estfan B; Byrne M; Kim R Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010 [TBL] [Abstract][Full Text] [Related]
9. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M; Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733 [TBL] [Abstract][Full Text] [Related]
11. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G; Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148 [TBL] [Abstract][Full Text] [Related]
14. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084 [TBL] [Abstract][Full Text] [Related]
15. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186 [TBL] [Abstract][Full Text] [Related]
16. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G; Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229 [TBL] [Abstract][Full Text] [Related]
17. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683 [TBL] [Abstract][Full Text] [Related]
20. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea. Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]